



October 23, 2009

Contact: Mary Campbell
Managing Director
EDF Ventures
(734) 663-3213

HandyLab to be Acquired by Becton, Dickinson and Company

Ann Arbor, MI -- EDF Ventures is proud to announce that HandyLab, one of its portfolio companies, will be acquired by Becton, Dickinson and Company (BD), according to BD's announcement prior to the opening of the market this morning. HandyLab, an Ann Arbor, Michigan-based company, develops and manufactures molecular diagnostic assays and automation platforms. The acquisition is subject to regulatory approvals and is expected to close during the first quarter of fiscal year 2010.

EDF co-founded the company with two scientists (Kaylan Handique and Sundu Brahmasandra), by providing the initial funding and negotiating the license for the technology from the University of Michigan. Mary Campbell, Managing Director of EDF, has played an active role in the company through her service on its Board of Directors.

"This company represents three hallmarks of EDF's investment strategy: investing early with the technical founders; investing in promising University technologies; and adhering to a capital efficient funding model," said Campbell.

At the time of the initial funding, HandyLab's CEO, Jeff Williams, was a member of EDF's advisory board. When asked about how the acquisition would impact HandyLab's business, Jeff said, "BD can help us expand the distribution very rapidly," Williams said. "It's a good outcome for our shareholders, for our employees and for our customers."

The move is consistent with BD's stated acquisition strategy, and builds upon a previously announced development and distribution agreement between BD and HandyLab executed earlier in 2009. This acquisition will expand BD's commitment to the novel HandyLab instrumentation technology to support BD's molecular diagnostics strategy.

"HandyLab has developed and commercialized a flexible automated platform for performing molecular diagnostics which is an ideal complement to our molecular diagnostics offerings," said Vincent A. Forlenza, BD President. "We believe this new platform enables both our healthcare-associated infections offering and future expansion into other molecular opportunities."

About EDF Ventures

EDF Ventures provides capital and leadership assistance to entrepreneurs with proprietary technology and a passion for building a company to uniquely meet the needs of a sector of the healthcare market. Located in Michigan, EDF invests throughout the country and is proud of its ability to attract as syndicate members several of the nation's leading healthcare venture investors. The EDF portfolio includes companies developing medical devices, clinical diagnostics and pharmaceuticals. Several of the EDF companies have their roots in universities. EDF manages three funds with approximately \$175 million under management. Visit www.edfvc.com for more information.

About HandyLab, Inc.

HandyLab is dedicated to the development, manufacture and sale of novel molecular diagnostic products. HandyLab's proprietary platform reduces the time, cost and complexity of testing while improving the quality of results. Using patented real time microfluidic PCR technology, HandyLab's products are positioned to decentralize nucleic acid testing. HandyLab is an Ann Arbor, Michigan based company. Additional information about the company can be found on the internet at www.handylab.com, or by calling 1-866-Handy Lab (1-866-426-3952).

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.